Regeneron Pharmaceuticals said its two-antibody “cocktail” REGN-COV2 met its primary endpoint of significantly reducing viral load and medical visits in ambulatory adults with COVID-19 in a Phase ...

REGN-COV2 consists of 2 virus-neutralizing antibodies that bind noncompetitively to the receptor binding domain of the SARS-CoV-2 spike protein. Positive results were announced from an ongoing phase 2 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 showing it ...

Phase II/III results presented at the Infectious Disease Society of America's IDWeek 2021 showed the cocktail, also known as REGEN-COV, met the study's primary endpoint of significantly reducing viral ...

Eli Lilly, Vir Biotechnology and GlaxoSmithKline said March 29 the COVID-19 antibody cocktail they are jointly developing reduced the viral load by 70 percent over a seven-day period compared to a ...